Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-07-13
2010-11-09
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S651000, C514S630000, C514S171000
Reexamination Certificate
active
07829554
ABSTRACT:
Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments of the composition are administered, for example, by injection, and/or transdermally.
REFERENCES:
patent: 4800079 (1989-01-01), Boyer
patent: 4826879 (1989-05-01), Yamamoto et al.
patent: 5126147 (1992-06-01), Silvestri et al.
patent: 5314916 (1994-05-01), York et al.
patent: 5496803 (1996-03-01), Meier et al.
patent: 6066675 (2000-05-01), Wen et al.
patent: 6110974 (2000-08-01), Aberg et al.
patent: 6656508 (2003-12-01), Goldenberg et al.
patent: 2002/0042404 (2002-04-01), Bauer et al.
patent: 2003/0022856 (2003-01-01), Richardson et al.
patent: 2004/0208910 (2004-10-01), Ashton et al.
patent: 2005/0069591 (2005-03-01), Bernstein et al.
patent: 2005/0113456 (2005-05-01), Aberg
patent: 2006/0189587 (2006-08-01), Bauer et al.
patent: 0120165 (1990-07-01), None
patent: 1153614 (2001-11-01), None
patent: 1867334 (2007-12-01), None
patent: 1471326 (1977-04-01), None
patent: 2443287 (2008-04-01), None
patent: 2453188 (2009-04-01), None
patent: WO 98/48810 (1998-11-01), None
patent: WO 01/28535 (1999-10-01), None
patent: WO 01/19373 (2001-03-01), None
patent: WO 03/033000 (2003-04-01), None
patent: WO 2004/028545 (2004-04-01), None
patent: WO 2004/091574 (2004-10-01), None
patent: WO 2004/103057 (2004-12-01), None
patent: WO 2004/103379 (2004-12-01), None
patent: WO 2005/007145 (2005-01-01), None
patent: WO 2005/072745 (2005-08-01), None
patent: WO 2006/122165 (2006-11-01), None
patent: WO 2007/011743 (2007-01-01), None
Johnson (Paediatric Respiratory Reviews, 2001, 2, 57-62).
Fuller et al. (Respiratory Medicine, 1995, 89, A, 3-18).
West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.
Johnson, M., “The β-Adrenoceptor”, Am J Respir Crit Care Med, 1998, vol. 158, No. 5, Nov. 1998, pp. S146-S153.
Reynisdottir, et al., “Effect of glucocorticosteroid treatment on β-adrenoceptor subtype function in adipocytes from patients with asthma,” Clinical Science, Effect of glucocorticosteroid treatment on beta-adrenoceptor subtype function in adipocytes from patients with asthma, 1993, pp. 237-244, 85 Great Britain.
O E Brodde, et al., Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen, The Journal of Clinical Investigation, 1985, pp. 1096-1101, 76 PubMed Central.
Peter Arner, PhD, MD, “Human fat cell lipolysis: Biochemistry, regulation and clinical role,” Best Practice & Research Clinical Endocrinology & Metabolism, 2005, pp. 471-482, vol. 19, Elsevier, Ltd.
EP 06787329.9 extended European search report dated Mar. 12, 2010.
GB 0718905.3 combined search and examination report dated Jan. 28, 2008.
GB 0718905.3 search report dated Nov. 27, 2008, claims 31-33.
GB 0718905.3 search report dated Nov. 27, 2008, claims 34-37 and 44.
GB 0718905.3 examination report dated Nov. 27, 2008.
AU2006270165 examiner's first report dated Dec. 24, 2009.
GB 0804401.8 search report dated Apr. 15, 2009.
PCT/US2007/079740 search report mailed Jan. 30, 2008.
EP 07871172 supplementary European search report dated Mar. 1, 2010.
PCT/US2007/081568 search report mailed Jun. 17, 2008.
Adcock, “Molecular interactions between glucocorticoids and long-acting β2-agonists,” J Allergy Clin Immunol 110(6 Suppl):S261-8 (2002).
Bronnegard et al., “Effect of glucocorticosteroid treatment on glucocorticoid receptor expression in human adipocytes,” J Clin Endocrinol Metab 80(12):3608-12 (1995).
Bujalska et al., “Characterisation of 11β-hydroxysteroid dehydrogenase 1 in human orbital adipose tissue: a comparison with subcutaneous and omental fat,” J Endocrinol 192(2):279-88 (2007).
Caruso et al., “Topical fat reduction from the waist,” Diabetes Obesity Metabolism 9:300-303 (2007).
Chung, “The complementary role of glucocorticosteroids and long-acting beta-adrenergic agonists,” Allergy 53(42 Suppl):7-13 (1998).
De Mazancourt et al., “Correction by dexamethasone treatment of the altered lipolytic cascade induced by adrenalectomy in rat adipocytes,” Horm Metab Res 22(1):22-4 (1990).
Farias-Silva et al., “Glucocorticoid receptor and Beta-adrenoceptor expression in epididymal adipose tissue from stressed rats,” Ann N Y Acad Sci 1018:328-32 (2004).
Fries, “Thyroid dysfunction: managing the ocular complications of Graves' disease,” Geriatrics 47(2):58-60, 63-4, 70 (1992).
Gibaud et al., “Poly(ε-caprolactone) and Eudragit microparticles containing fludrocortisone acetate,” Int J Pharm 28;269(2):491-508 (2004).
Gittoes and Franklyn, “Hyperthyroidism. Current treatment guidelines,” Drugs 55(4):543-53 (1998).
Hadcock and Malbon, “Regulation of β-adrenergic receptors by “permissive” hormones: glucocorticoids increase steady-state levels of receptor mRNA,” Proc Natl Acad Sci U S A 85(22):8415-9 (1988).
Kendall-Taylor et al., “Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy,” BMJ 297(6663):1574-8 (1988).
Lacasa et al., “Permissive action of glucocorticoids on catecholamine-induced lipolysis: direct “in vitro” effects on the fat cell beta-adrenoreceptor-coupled-adenylate cyclase system,” Biochem Biophys Res Commun 153(2):489-97 (1988).
Langley et al., “Perioperative management of the thyrotoxic patient,” Endocrinol Metab Clin North Am 32(2):519-34 (2003).
Mak et al., “Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo,” J Clin Invest 96(1):99-106 (1995).
Marcocci et al., “Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study,” Clin Endocrinol (Oxf) 27(1):33-42 (1987).
Mirkin, “Albuterol for weight control,” www.DrMirkin.com (2009).
Page et al., “β-Adrenergic receptor agonists increase apoptosis of adipose tissue in mice,” Domest Anim Endocrinol 26(1):23-31 (2004).
Pedersen et al., “Anti-glucocorticoid effects of progesterone in vivo on rat adipose tissue metabolism,” Steroids 68:543-550 (2003).
Risse-Sundermann, “The treatment of alopecia areata by intradermal injections of microcrystallized prednisone trimethylacetate,” Dtsch med Wochenschr 85(15):584-586 (1960).
Seco et al., “Acute and chronic treatment with glucocorticosteroids, modifying the beta 2-adrenergic response of the guinea pig trachea,” Lung 173(5):321-8 (1995).
Wiersinga and Prummel, “Graves' ophthalmopathy: a rational approach to treatment,” Trends Endocrinol Metab 13(7):280-7 (2002).
Dobak, “Formulations For Treatment Of Adipose Tissue, Cutaneous Tissue And Disorders, And Muscular Tissue,” U.S. Appl. No. 12/445,571, filed Jan. 22, 2010.
Dobak, “Methods, Compositions, And Formulations For The Treatment Of Thyroid Eye Disease,” U.S. Appl. No. 12/445,570, filed Jan. 12, 2010.
Reynisdottir, et al., “Effect of glucocorticosteroid treatment on β-adrenoceptor subtype function in adipocytes from patients with asthma,” Clinical Science, Effect of glucocorticosteroid treatment on beta-adrenoceptor subtype function in adipocytes from patients with asthma, 1993, pp. 237-244, 85 Great Britain.
O E Brodde, et al., Terbutaline-induced desensitization of human lymphocyte beta 2-adrenoceptors. Accelerated restoration of beta-adrenoceptor responsiveness by prednisone and ketotifen, The Journal of Clinical Investigation, 1985, pp. 1096-1101,
Lithera, Inc.
Padmanabhan Sreeni
Ramachandran Umamaheswari
Wilson Sonsini Goodrich & Rosati
LandOfFree
Sustained release enhanced lipolytic formulation for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sustained release enhanced lipolytic formulation for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release enhanced lipolytic formulation for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244283